A phase 1 study of RES030-085
Latest Information Update: 28 May 2021
At a glance
- Drugs RES030-085 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions
Most Recent Events
- 28 May 2021 New trial record
Latest Information Update: 28 May 2021